[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myeloproliferative-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myeloproliferative-syndrome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,54,101,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100434327","phase-2-faecal-microbiota-transplantation-after-allogeneic-stem-cell-transplantation-100434327",false,"NCT04935684","Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation","Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies","TMF-Allo","Inclusion Criteria:\n\n* Patient aged 18 or over\n* Men and women\n* Patients affiliated with a social-security organization\n* Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Status of tumor progression at the time of allo-HSCT\n* Inability to understand the protocol (linguistic barrier, cognitive difficulties)\n* Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma)\n* Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis)\n* Fecal incontinence\n* Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication.\n* Pregnant women\n* Patient under guardianship, curatorship or protection of justice","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).\n\nThe hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.",[27,28,29,30,31,32,33],"Acute Leukemia in Remission","Myelodysplastic Syndromes","Myeloproliferative Syndrome","Hodgkin Lymphoma","Lymphoma, Non-Hodgkin","Myeloma","Chronic Lymphocytic Leukemia",[35,36,37,38,39,40],"Allogeneic hematopoietic stem cell transplantation","Hematologic malignancies","Graft versus Host Disease","Intestinal microbiota","Intestinal dysbiosis","Fecal Microbiota Transplantation","RECRUITING","2026-06-08",{"date":44,"type":45},"2026-06-09","ACTUAL",{"date":47,"type":45},"2022-12-20",{"date":49,"type":21},"2030-05",{"name":51,"class":52},"University Hospital, Clermont-Ferrand","OTHER",20,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":67,"conditions":68,"keywords":78,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100248087","phase-1-alphabeta-cd19-depleted-haploidentical-transplantation--zometa-for-pediatric-hematologic-malignancies-and-solid-tumors-100248087","NCT02508038","Alpha\u002FBeta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors","TCR-αβ+ and CD19+ Depleted KIR\u002FKIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed\u002FRefractory Hematologic Malignancies and High Risk Solid Tumors","Inclusion Criteria:\n\n* Availability of an eligible haploidentical donor\n* Hematologic malignancy or solid tumor\n* Patients with more than one malignancy (hematologic or solid tumor) are eligible\n* Patients with hematologic malignancy must have no HLA identical sibling or suitable unrelated donor OR time needed to find an acceptable unrelated donor match would likely result in disease progression such that the patient may become ineligible for any type of potentially curative transplant\n\n  * Relapsed or primary therapy-refractory AML with bone marrow blast \\\u003C 20%\n  * High-risk refractory or relapsed ALL in patients for whom transplantation is deemed indicated (relapse occurring \\\u003C 30 months from diagnosis, patients relapsing after previous allogeneic transplant, relapse after 2nd remission, primary induction failure or hypodiploidy)\n  * Relapsed Hodgkin lymphoma unable to achieve 2nd remission or Very Good Partial Response (VGPR) and therefore ineligible to receive autologous hematopoietic stem cell transplant (auto-HSCT)\n  * Hodgkin lymphoma relapsing after auto-HSCT\n  * Primary refractory or relapsed non-Hodgkin lymphoma unable to achieve 2nd remission or VGPR and therefore ineligible to receive auto-HSCT\n  * Non-Hodgkin lymphoma relapsing after auto-HSCT\n  * Myelodysplastic Syndrome\u002FMyeloproliferative Syndrome\n\nSolid Tumor\n\n* Patients with solid tumor must have failed or have been ineligible to receive auto-HSCT or if auto-HSCT would not offer \\> 20% chance of cure\n* Neuroblastoma\n\n  * high risk with relapsed or refractory disease\n* Soft tissue sarcomas (Rhabdomyosarcoma, Ewing sarcoma, Primitive Neuroectodermal Tumor or other high-risk extracranial solid tumors)\n\n  * Relapsed or primary refractory metastatic\n  * 1st complete remission, but very high-risk features (i.e., \\\u003C 20% survival with conventional therapy)\n* Osteosarcoma\n\n  * Failure to achieve Complete Response (CR) following initial therapy\n  * Relapsed with pulmonary or bone metastases and did not achieve a CR with surgery and\u002For chemotherapy\n* Karnofsky (patients \\> 16 years) or Lansky (patients 16 years or older) performance score of ≥ 60\n* Life expectancy of ≥ 3 months\n* Patient must have fully recovered from acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\n* Study enrollment no earlier than 3 months after preceding HSCT\n* Glomerular Filtration Rate (GFR) ≥ 60 ml\u002Fmin\u002F1.73m2\n* Total bilirubin \\\u003C 3 mg\u002FdL\n* ALT (alanine aminotransferase, SCPT) ≤ 5 x Upper LImit of Normal (ULN) for age\n* Ejection fraction of \\> 40% by Multigated Acquisition Scan (MUGA) or echocardiogram\n* No evidence of dyspnea at rest\n* No supplemental oxygen requirement\n* If measured, carbon monoxide diffusion capacity (DLCO) \\>50%\n* No severe peripheral neuropathy, signs of leukoencephalopathy or active Central Nervous System (CNS) infection\n* Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsant therapy\n* If of reproductive potential, negative pregnancy test and willing to use effective birth control method\n* Informed consent from patient or legal guardian (if patient is minor)\n\nInclusion Criteria for Donors:\n\n* Donor must be 18 years of age minimum, 65 years of age maximum\n* Donor must be in good general health as determined by evaluating medical provider\n* Must meet donor criteria for human cells, tissues, and cellular and tissue-based products per Code of Federal Regulations 21 CFR 1271, subpart C. Specifically:\n\n  * Donor screening in accordance with 1271.75 indicates that the donor:\n\n    * Is free from risk factors for, and clinical evidence of, infection due to relevant communicable disease agents and diseases; and\n    * Is free from communicable disease risks associated with xenotransplantation; and\n  * The results of donor testing for relevant communicable disease agents in accordance with 1271.80 and 1271.85 are negative or nonreactive, except as provided in 1271.80(d)(1).\n* Haploidentical by HLA-typing\n* Preference will be given to donors who demonstrate KIR incompatibility with recipient HLA class I ligands defined as the donor expressing a KIR gene for which the corresponding HLA class I ligand is not expressed by the recipient.\n* Negative testing for relevant communicable diseases:\n\n  * Hepatitis B surface antigen (HBsAg)\n  * Hepatitis B core antibody (Anti-HBc)\n  * Hepatitis C antibody (Anti-HCV)\n  * HIV 1 \\& 2 antibody (Anti-HIV-1, 2 plus O)\n  * HTLV I\u002FII antibody (Anti-HTLV I\u002FII)\n  * RPR (Syphilis TP)\n  * CMV (Capture CMV)\n  * MPX for: HepB (HBV-PCR), HepC (HCV-PCR), HIV (HIV-PCR)\n  * NAT for West Nile Virus (WNV-PCR)\n  * T. Cruzi - EIA (Chagas)\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding\n* HIV infection\n* Heart failure or uncontrolled cardiac rhythm disturbance\n* Uncontrolled, Serious Active Infection\n* Prior organ allograft\n* Significant serious intercurrent illness unrelated to cancer or its treatment not covered by other exclusion criteria expected to significantly increase the risk of HSCT\n* Any mental or physical condition, in the opinion of the PI (or PI designee), which could interfere with the ability of the subject (or the only parent or legal guardian available to care for the subject) to understand or adhere to the requirements of the study\n* Enrollment in any other clinical study from screening up to Day 100 (unless PI judges such enrollment would not interfere with endpoints of this study)\n\nExclusion Criteria for Donors:\n\n* Lactating females\n* Pregnant females","7 Months","21 Years",{"count":64,"type":21},22,[66],"PHASE1","This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors.",[69,70,30,71,72,29,73,74,75,76,77],"Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Non-Hodgkin Lymphoma","Myelodysplastic Syndrome","Rhabdomyosarcoma","Ewing Sarcoma","Primitive Neuroectodermal Tumor","Osteosarcoma","Neuroblastoma",[79,80,81,82,83,84,85,86,87,88,89,90],"alpha beta depleted","alphabeta","TCR alpha beta depleted","alpha beta","haploidentical","Zoledronate","Zoledronic acid","Pediatric cancers","alfa beta","αβ T cell depleted HSCT","alpha beta T cell and B cell depleted HSCT","haploidentical HSCT","2025-10-14",{"date":93,"type":45},"2025-10-16",{"date":95,"type":45},"2016-02-12",{"date":97,"type":21},"2027-12",{"name":99,"class":52},"University of Wisconsin, Madison",1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":107,"enrollmentInfo":108,"targetDuration":110,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100436866","protocol-for-genomically-profiling-collecting-archiving-and-distributing-blood-and-bone-marrow-specimens-from-children-and-young-adults-with-hematologic-malignancy-100436866","NCT04968834","Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic Malignancy","Inclusion Criteria:\n\n* Age: birth to \\\u003C 30 years of age\n* Diagnosis:\n\n  \\-- Patient with acute leukemia, chronic leukemia, MDS\u002FAML, myelodysplastic syndrome or myeloproliferative syndromes. Disease can be newly diagnosed or relapsed\u002Frefractory.\n* Pathology Criteria:\n\n  \\-- Histologic confirmation of leukemia or myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS) at the time of diagnosis or recurrence\n* Specimen Criteria:\n\n  * Sufficient sample available for genomic profiling OR bone marrow aspirate\u002Fblood draw planned for clinical care which is anticipated to allow collection of minimum specimen for testing (See Section 6.1 for description of specimen requirements)\n\nExclusion Criteria:\n\n\\- Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence (See Section 6.1); or bone marrow evaluations NOT planned for clinical care; or peripheral blast percentage \\\u003C20%, or clinical blood draw not planned","30 Years",{"count":109,"type":21},300,"5 Years","OBSERVATIONAL","This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and work. Genes are composed of DNA letters that spell out these instructions. Genomic profiling helps investigators understand why the disease develops and the instructions that led to its development. Understanding the genetic factors of the disease can also help investigator understand why the disease of some people can respond to certain therapies differently than others.\n\nThe genomic profiling will be performed using bone marrow and blood samples that either have already been obtained during a previous clinical procedure or will be obtained at the time of a scheduled clinical procedure. Studying the genetic information in the cells of these samples will provide information about the origin, progression, and treatment of leukemia and myeloproliferative syndromes and myelodysplastic syndrome. Storing the bone marrow and blood samples will allow for additional research and genomic assessments to be performed in the future.",[114,28,29],"Leukemia",[114,28,116],"Myeloproliferative syndrome (MPS)","2025-06-09",{"date":119,"type":45},"2025-06-12",{"date":121,"type":45},"2021-06-11",{"date":123,"type":21},"2033-06",{"name":125,"class":52},"Dana-Farber Cancer Institute",8,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":148,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100351175","phase-2-allogeneic-hematopoietic-cell-transplantation-from-hla-matched-donor-after-flu-mel-ptcy-versus-flu-mel-atg-reduced-intensity-conditioning-100351175","NCT03852407","Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning: a Phase II Randomized Study From the Belgian Hematology Society (BHS)","HLA","Inclusion Criteria:\n\nPatients V.1.1. Diseases\n\nHematological malignancies confirmed histologically:\n\n* AML in morphological CR or not in morphological CR but not rapidly progressing (i.e. no need to give treatments such as hydroxyurea to maintain WBC count \\\u003C 10 000 x109\u002FmL);\n* MDS;\n* CML in CP or AP;\n* MPD not in blast crisis,\n* MDS\u002FMPD overlap,\n* ALL in CR;\n* Multiple myeloma;\n* CLL;\n* Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);\n* Hodgkin's disease with chemosensitive disease or responding to checkpoint inhibitors.\n\n  \\* Clinical situations\n\n  • Theoretical indication for a standard allo-transplant, but not feasible because:\n* Age \\> 50 yrs;\n* Unacceptable end organ performance;\n* The physician's decision;\n* The patient's decision\n\n  * Underlying 'lower risk' disease, for which Reduced Intensity Conditioning is preferred (eg CLL, MCL)\n\n    \\* Other inclusion criteria\n  * Male or female; fertile patients must use a reliable contraception method;\n  * Age 18-75 yrs (children of any age are not allowed in the protocol);\n  * Informed consent given by patient or his\u002Fher guardian if indicated.\n\nDonors\n\n* Male or female;\n* Any age;\n* Human Leukocyte Antigen (HLA)-identical sibling donor or 10 of 10 (HLA-A, -B, -C, -DRB1, and -DQB1) HLA allele matched unrelated donor;\n* Weight \\> 15 Kg (because of leukapheresis);\n* Fulfills criteria for allogeneic Peripheral Blood Stem Cell (PBSC) donation according to standard procedures;\n* Informed consent given by donor or his\u002Fher guardian if indicated, as per donor center standard procedures.\n\nExclusion Criteria:\n\nPatients\n\n* Any condition not fulfilling inclusion criteria;\n* Human Immunodeficiency Virus positive;\n* Non-hematological malignancy(ies) (except non-melanoma skin cancer) active \\\u003C 3 years before Hematopoietic Cell Transplantation (HCT).\n* Life expectancy severely limited by disease other than malignancy;\n* Central Nervous System involvement with disease refractory to intrathecal chemotherapy.\n* Terminal organ failure, except for renal failure (dialysis acceptable)\n\n  1. Cardiac: Symptomatic coronary artery disease; ejection fraction \\\u003C40%; uncontrolled arrhythmia, uncontrolled hypertension;\n  2. Pulmonary: Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)\\\u003C 40% and\u002For receiving supplementary continuous oxygen, Forced Expiratory Volume in 1 Second (FEV1)\\\u003C 40%;\n  3. Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin \\>3 mg\u002FdL, and symptomatic biliary disease;\n* Uncontrolled infection;\n* Karnofsky Performance Score \\\u003C70%;\n* Patient is a fertile man or woman who is unwilling to use contraceptive techniques during and for 12 months following treatment;\n* Patient is a female who is pregnant or breastfeeding;\n* Any condition precluding the use of melphalan or Thymoglobulin;\n\nDonors\n\n* Any condition not fulfilling inclusion criteria;\n* Unable to undergo leukapheresis because of poor vein access or other reasons.","75 Years",{"count":137,"type":21},114,[24],"The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG\u002FPTCy) to 45% (Pick-a-winner phase 2 randomized study).",[141,28,142,29,143,144,145,146,147,30],"Acute Myeloid Leukemia in Remission","Chronic Myeloid Leukemia in Remission","Myeloproliferative Disorder","Acute Lymphoid Leukemia in Remission","Multiple Myeloma","Chronic Lymphoid Leukemia","Non Hodgkin Lymphoma",[149,150,151,152,153,154,155,156,157,158,159],"hematological malignancies","Graft versus host disease","GVHD","Progression free survival","Allogeneic hematopoeitic cell transplantation","HLA-matched donor","reduced intensity conditioning","Overall survival","ATG PK","Immunosuppressive regimen","Prophylaxis","2022-10-11",{"date":162,"type":45},"2022-10-12",{"date":164,"type":45},"2019-02-04",{"date":166,"type":21},"2038-11-01",{"name":168,"class":52},"University of Liege",10]